209 related articles for article (PubMed ID: 11867750)
1. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
Koo HM; VanBrocklin M; McWilliams MJ; Leppla SH; Duesbery NS; Vande Woude GF
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3052-7. PubMed ID: 11867750
[TBL] [Abstract][Full Text] [Related]
2. Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.
Duesbery NS; Vande Woude GF
J Appl Microbiol; 1999 Aug; 87(2):289-93. PubMed ID: 10475971
[TBL] [Abstract][Full Text] [Related]
3. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.
Duesbery NS; Resau J; Webb CP; Koochekpour S; Koo HM; Leppla SH; Vande Woude GF
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):4089-94. PubMed ID: 11259649
[TBL] [Abstract][Full Text] [Related]
4. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Abi-Habib RJ; Singh R; Leppla SH; Greene JJ; Ding Y; Berghuis B; Duesbery NS; Frankel AE
Clin Cancer Res; 2006 Dec; 12(24):7437-43. PubMed ID: 17189417
[TBL] [Abstract][Full Text] [Related]
5. Anthrax lethal toxin disrupts the endothelial permeability barrier through blocking p38 signaling.
Liu T; Milia E; Warburton RR; Hill NS; Gaestel M; Kayyali US
J Cell Physiol; 2012 Apr; 227(4):1438-45. PubMed ID: 21618534
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
Huang D; Ding Y; Luo WM; Bender S; Qian CN; Kort E; Zhang ZF; VandenBeldt K; Duesbery NS; Resau JH; Teh BT
Cancer Res; 2008 Jan; 68(1):81-8. PubMed ID: 18172299
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhizin induces melanogenesis by elevating a cAMP level in b16 melanoma cells.
Lee J; Jung E; Park J; Jung K; Park E; Kim J; Hong S; Park J; Park S; Lee S; Park D
J Invest Dermatol; 2005 Feb; 124(2):405-11. PubMed ID: 15675961
[TBL] [Abstract][Full Text] [Related]
8. Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin.
Bromberg-White J; Lee CS; Duesbery N
Toxins (Basel); 2010 May; 2(5):1038-53. PubMed ID: 22069624
[TBL] [Abstract][Full Text] [Related]
9. Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways.
Bromberg-White JL; Duesbery NS
Methods Enzymol; 2008; 438():355-65. PubMed ID: 18413261
[TBL] [Abstract][Full Text] [Related]
10. p44/42 MAPK signaling is a prime target activated by phenylethyl resorcinol in its anti-melanogenic action.
Kang M; Park SH; Park SJ; Oh SW; Yoo JA; Kwon K; Kim J; Yu E; Cho JY; Lee J
Phytomedicine; 2019 May; 58():152877. PubMed ID: 30849679
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Substrate-selective Exosite within the Metalloproteinase Anthrax Lethal Factor.
Goldberg AB; Cho E; Miller CJ; Lou HJ; Turk BE
J Biol Chem; 2017 Jan; 292(3):814-825. PubMed ID: 27909054
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.
Alfano RW; Leppla SH; Liu S; Bugge TH; Meininger CJ; Lairmore TC; Mulne AF; Davis SH; Duesbery NS; Frankel AE
Mol Cancer Res; 2009 Apr; 7(4):452-61. PubMed ID: 19372576
[TBL] [Abstract][Full Text] [Related]
13. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition.
Park JM; Greten FR; Li ZW; Karin M
Science; 2002 Sep; 297(5589):2048-51. PubMed ID: 12202685
[TBL] [Abstract][Full Text] [Related]
14. Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs.
Bardwell AJ; Abdollahi M; Bardwell L
Biochem J; 2004 Mar; 378(Pt 2):569-77. PubMed ID: 14616089
[TBL] [Abstract][Full Text] [Related]
15. Anthrax lethal factor represses glucocorticoid and progesterone receptor activity.
Webster JI; Tonelli LH; Moayeri M; Simons SS; Leppla SH; Sternberg EM
Proc Natl Acad Sci U S A; 2003 May; 100(10):5706-11. PubMed ID: 12724519
[TBL] [Abstract][Full Text] [Related]
16. Critical role of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway in recovery from anthrax lethal toxin-induced cell cycle arrest and MEK cleavage in macrophages.
Ha SD; Ng D; Pelech SL; Kim SO
J Biol Chem; 2007 Dec; 282(50):36230-9. PubMed ID: 17951252
[TBL] [Abstract][Full Text] [Related]
17. Anthrax lethal factor inhibitors as potential countermeasure of the infection.
Kumar BV; Malik S; Grandhi P; Dayam R; Sarma JA
Curr Top Med Chem; 2014; 14(17):1977-89. PubMed ID: 25262802
[TBL] [Abstract][Full Text] [Related]
18. Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation.
Ouyang W; Guo P; Fang H; Frucht DM
J Biol Chem; 2017 Oct; 292(43):17919-17927. PubMed ID: 28893904
[TBL] [Abstract][Full Text] [Related]
19. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor.
Depeille P; Young JJ; Boguslawski EA; Berghuis BD; Kort EJ; Resau JH; Frankel AE; Duesbery NS
Clin Cancer Res; 2007 Oct; 13(19):5926-34. PubMed ID: 17908989
[TBL] [Abstract][Full Text] [Related]
20. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.
Abi-Habib RJ; Urieto JO; Liu S; Leppla SH; Duesbery NS; Frankel AE
Mol Cancer Ther; 2005 Sep; 4(9):1303-10. PubMed ID: 16170021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
